AI can help inform the personalized dose of radiation to treat cancer patients, with the technology using information from medical scans and EHRs, according to researchers from Cleveland Clinic.

Gadolinium-based contrast agents (GBCAs) can often bring out the best in MRI, but they’re controversial and thus increasingly avoided. A pilot study in Germany shows how an algorithm might substitute for an injection to track tumors of the brain and spinal cord (aka gliomas).

An Irish AI startup whose investors have already raised $65 million is pledging to deliver a breakthrough natural food additive by the end of this year and four more by 2021.

Aided by augmented reality, AI and portable neuroimaging technology, physicians may soon be able to tease out images of patients’ brains—right there in the doctor’s office—to see how much pain each patient is suffering.

Healthcare AI isn’t yet good enough to reliably deliver on its promises where it stands to make the biggest difference—and it doesn’t have enough high-quality data to get there anytime soon.

Only one-fifth of consumers would trust healthcare advice from AI-generated communications, according to a recent poll.

The Massachusetts Medical Society, which publishes the New England Journal of Medicine, on June 19 named Eric J. Rubin, MD, PhD, as the newest editor-in-chief of the Journal and NEJM Group.

An initial set of studies went up this week at medRxiv, a new and somewhat controversial online outlet hosting preprinted clinical research reports—they haven’t yet been subject to peer review, much less journal editing—and the batch includes one dealing with AI.